Products in Development

Mira Dx®  is developing evidence that their proprietary markers that predict cancer risk assessment can also predict therapeutic response (Companion Diagnostics). Mira Dx® is also further developing the potential of their miRNA signatures to help better determine the site of origin of tumors. Developed tests will be offered through our CLIA laboratory based in New Haven, Connecticut.

Mira Dx® Research and Development Program

 
MDX0020: The potential of the KRAS-variant as a companion diagnostic

MDX0030: MiRNA signature differentiating uterine and ovarian papillary serous tumors

MDX0040: The role of the KRAS-variant in directing treatment of endometriosis

MDX0050: The role of the KRAS-variant in directing hormone replacement therapy